Lead Pharma is a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer. It has entered into a research collaboration with big-shot Sanofi to develop small molecule therapies directed against the nuclear hormone receptor ROR gamma t (RORyt) to treat a broad range of autoimmune disorders. A big news for this Netherland-based Biotech company.
A wide range of human diseases are driven by deregulated immune function, including joint diseases such as rheumatoid arthritis, inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Often, these diseases are characterized by inappropriate activation of molecules termed cytokines, which are important mediators of normal immune function. When inappropriately activated, these powerful molecules can cause severe damage to multiple body systems. The RORyt is a key regulator of the cytokine immune pathway and its function can be moderated with small molecules, advancing this target to the cutting edge of drug discovery.
Christian Antoni, Vice President and Head of the Immunology & Inflammation Franchise, Research and Development at Sanofi,